Skip to content
Research Article Open access CC BY 3.0

Role of Serum Adiponectin, IL-6 and Hs CRP in Nonalcoholic Fatty Liver Egyptian Patients

Amal Ahmed Mohamed, Wafaa Gh. Shousha, Olfat Shaker, Mohamed El-Sayed Mahdy, Eman M. A. Ibrahim, Seham Mohmoud, Ahmed khairalla

International Journal of Biochemistry Research & Review · pp. 493–504 · Published 25 Jun 2014

10.9734/IJBCRR/2014/10240

Abstract

Scientific Background: Non alcoholic fatty liver (NAFLD) is accumulation of fat in the liver cells of peoples who drink little or no alcohol causing mild steatosis with mostly no signs, symptoms or complication but this may progress to steatohepatitis (NASH) and may liver cirrhosis then failure. NAFLD is recognized as the most common type of chronic liver disease in Western countries and the leading cause of cryptogenic cirrhosis. Insulin resistance (IR) is a key factor in the pathogenesis of NAFLD, the latter being considered as the hepatic component of IR or metabolic syndrome (MetS). Although the pathogenesis of NAFLD is not fully elucidated, a complex interaction between adipokines and cytokines produced by adipocytes and/or inflammatory cells infiltrating adipose tissue appears to play a crucial role in MetS and NAFLD and its progress.  A number of factors are linked with NAFLD such as obesity, type 2 diabetis mellitus (T2DM), hyperlipidemia, gastric bypass, and its progress to NASH correlate with certain cytokines secreted like adiponectin, interlukin-6 (IL-6), and C- reactive protein CRP. Adiponectin is a novel adipocyte-specific protein, which, it has been suggested, plays a role in the development of insulin resistance and atherosclerosis. The role of (IL-6) in liver pathology is very complex, and its participation in the development of NAFLD remains unclear. IL-6 is a key element in the acute phase response, mediating the synthesis of several acute phase proteins (such as CRP and serum amyloid A). Thus, we cannot exclude the possibility that IL-6 might also play an indirect deleterious role in NAFLD pathogenesis. In diet-induced obese mice, treatment with IL-6 antibodies improved sensitivity to insulin. Objective: This study aim is to evaluate the level of adiponectin, IL-6 and CRP in Egyptian patients with NAFLD. Methods: This study was conducted on 2 groups 104 NAFLD as diagnosed by ultrasound examination and 21 healthy participants as control group.  All the subjects were subjected to an abdominal ultrasonography, liver enzymes ALT & AST, lipid profile (triglycerides, HDL, LDL, cholesterol, CRP, IL-6 & Adiponectin). Results: Plasma adiponectin levels were significantly lower in NAFLD patients than control gp (3.05±2.65μg/ml vs 10.52±3.35 (μg/ml). IL-6 level was higher in NAFLD than control gp but not significant (114.24±22.32pg/ml vs 104.9±19.98pg/ml). CRP was significantly higher in NAFLD than control gp (17.86±11.59mg/L vs 5.4±3.81mg/L). Adiponectin ROC curve showed an AUROC curve in NAFLD gp (0.918 p=0.0001). IL-6 ROC curve showed an AUROC curve in NAFLD gp (0.703 p=0.0003). CRP ROC curve showed an AUROC curve in NAFLD gp (0.853 p=0.0001). Conclusion: Patients with NAFLD have lower adiponectin levels and higher IL-6 and CRP levels compared with their control group.

MetS metabolic syndrome NAFLD Non alcoholic fatty liver disease IL-6 interleukin-6

References (44)

  1. 1 Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge [DOI]
  2. 2 Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease [DOI]
  3. 3 Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia [DOI]
  4. 4 Adiponectin and Adiponectin Receptors [DOI]
  5. 5 C-Reactive Protein in Healthy Subjects: Associations With Obesity, Insulin Resistance, and Endothelial Dysfunction [DOI]
  6. 6 Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses [DOI]
  7. 7 Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma [DOI]
  8. 8 AGA technical review on nonalcoholic fatty liver disease [DOI]
  9. 9 Beyond insulin resistance in NASH: TNF-α or adiponectin? [DOI]
  10. 10 IL-6: from its discovery to clinical applications [DOI]
  11. 11 Ultrasound scanning in the detection of hepatic fibrosis and steatosis. [DOI]
  12. 12 Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis [DOI]
  13. 13 Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis [DOI]
  14. 14 Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease [DOI]
  15. 15 Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity [DOI]
  16. 16 Nonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines [DOI]
  17. 17 Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus [DOI]
  18. 18 Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds [DOI]
  19. 19 The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease [DOI]
  20. 20 Interleukin-6 Depletion Selectively Improves Hepatic Insulin Action in Obesity [DOI]
  21. 21 Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity [DOI]
  22. 22 Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases [DOI]
  23. 23 Cytokines in the Pathogenesis of Fatty Liver and Disease Progression to Steatohepatitis: Implications for Treatment [DOI]
  24. 24 Metabolic and Adipokine Profile of Chinese Patients With Nonalcoholic Fatty Liver Disease [DOI]
  25. 25 Abdominal Obesity and Fatty Liver [DOI]
  26. 26 Review article: current management of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis [DOI]
  27. 27 Non Alcoholic Fatty Liver Disease in Southern Iran: A Population Based Study [DOI]
  28. 28 IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver.
  29. 29 Adiponectin, hepatocellular dysfunction and insulin sensitivity [DOI]
  30. 30 NAFLD, Obesity, and Bariatric Surgery [DOI]
  31. 31 Serum C-reactive protein as a marker for wellness assessment.
  32. 32 IL-6 Deficiency Attenuates Murine Diet-Induced Non-Alcoholic Steatohepatitis [DOI]
  33. 33 Interleukin-6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischaemic preconditioning in mice [DOI]
  34. 34 Non-Alcoholic Fatty Liver Disease Is Closely Associated with Sub-Clinical Inflammation: A Case-Control Study on Asian Indians in North India [DOI]
  35. 35 Adiponectin: A multitasking player in the field of liver diseases [DOI]
  36. 36 Adiponectin--an adipokine with unique metabolic properties [DOI]
  37. 37 Insulin resistance and metabolic syndrome in chronic liver diseases: Old entities with new implications [DOI]
  38. 38 High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population [DOI]
  39. 39 The serum profile of adipokines in overweight patients with metabolic syndrome.
  40. 40 Hypoadiponectinemia and Insulin Resistance are Associated with Nonalcoholic Fatty Liver Disease [DOI]
  41. 41 Association Among C-Reactive Protein, Fatty Liver Disease, and Cardiovascular Risk [DOI]
  42. 42 Metabolic syndrome, non-alcoholic steatohepatitis (NASH), and hepatocyte growth factor (HGF) [DOI]
  43. 43 Plasma levels of interleukin-6 and interleukin-8 in Chinese patients with non-alcoholic fatty liver disease.
  44. 44 Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis.

Cited by 11

Correlation between Anthropometric Measures, Lipid Profile and Serum Adiponectin and Steatosis in Nondiabetic Nonalcoholic Fatty Liver Disease

Hasan S. Mahmoud, Mohamad M. Helal, Mohammed H. Hassan, Mahmoud F. Sherif · Journal of Advances in Medicine and Medical Research · 2015

STATUS OF 25-HYDROXYVITAMIN D LEVELS AND SERUM CONCENTRATION OF PROINFLAMMATORY CYTOKINES (IL-6 AND TNF-Α) IN MIDDLE-AGED TRIBAL SUBJECTS OF TRIPURA

Arkadip Choudhury, Avik Chakraborty, Animesh Saha · Journal of Evolution of Medical and Dental Sciences · 2018

Effect of bortezomib on fatty liver in a rat model of atherosclerosis

Ismawati, Ilhami Romus, Enikarmila Asni · Biomedicine · 2022

The promising role of CCL2 as a noninvasive marker for nonalcoholic steatohepatitis diagnosis in Egyptian populations

Ahmed Amin Ali, Aya Fouda, El sayed Abdelaziz · European Journal of Gastroenterology & Hepatology · 2021

Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass

Vasily Isakov · World Journal of Gastroenterology · 2025

Showing 5 of 11 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

78

Page views

0

PDF downloads

48

Outbound clicks

11

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.